

Investment Thesis

Overview

Mammoth Private Capital invests in early to growth stage life science and bio tech companies. We seek to add value through a deep functional understanding of healthcare delivery, contracting, private and CMS reimbursement, creation of new CMS reimbursement pathways, FDA, EU and data regulatory requirements and informative data technologies. Additionally, our team has strong relationships with leading physician, surgeon, healthcare executive and financial technology thought leaders in the US and around the world.

Our Objective

Mammoth Scientific's objective is to generate top quartile returns through the long-term capital appreciation of investments in private companies. These investments will be structured as equity, convertible securities and other equity-related investments in the healthcare and information technology sectors, and are expected to include portfolio companies specializing in medical devices, infrastructure, information technology, financial technology, biotechnology, wellness and life sciences.

Our Focus

Our focus will be on exceptional founder teams who own proprietary technology. We place a strong emphasis on investing in companies that address economically meaningful, and previously unmet, clinical needs in a manner that minimizes binary scientific risk. A well-defined regulatory and reimbursement pathway is also expected (whether already in place or one that our Mammoth experts can envision as added-value to the portfolio company).

Why Now

As the past year has dramatically demonstrated, healthcare and technology are perhaps the most critical components of the national and global economy. Innovation in healthcare, already vigorous, has been dramatically accelerated by the massive amounts of spending on fundamental and clinical life science research over the past year. Technological advancements to provide greater value to individuals and businesses alike have significantly accelerated to meet new needs for distanced transactions and relationships. We believe the healthcare and technology sectors, coupled with the pre-existing trends of an aging population, increase in chronic diseases and an increasingly affluent populace seeking longevity and a better quality of life, are poised for substantial growth over the next decade.

Scientific & Investment Review



Jay Yadav, MD
Chief Investment Officer (CIO)



Matthew McGirt, MD
Vice-President of Clinical & Commercial Development



Tommy Martin, CFP®, CPWA®
Chief Executive Officer (CEO)



Kim Mackrill
Chief Operating Officer (COO)



Jud Mackrill
Chief Experience Officer (CXO)

The Challenge

Although investments in healthcare present a large economic opportunity and strong tailwind as a result of heavy R&D throughout the Covid pandemic, it is challenging for investors to take advantage of earlier stage healthcare opportunities due to the structural, regulatory and reimbursement complexities of the healthcare system. Similarly, we believe the unique complexities of technology, specifically financial technology, have been highlighted by recent volatility and the continued rapid decentralization¹. Innovation to keep and expand financial reach, including the massive wealth transfer (\$68 Trillion) from an aging population to Baby Boomers and Generation X, has been expedited as virtual processing has become a necessity.²

Why Mammoth

The Mammoth team is led by highly successful and seasoned physician entrepreneurs and operational managers some of whom have a twenty year track record of creating and investing in multiple successful startups with large exits to major global companies (Abbott Laboratories, Boston Scientific, Johnson & Johnson) or the public markets.

We expect our deep functional understanding of healthcare delivery, contracting, private and CMS reimbursement, creation of new CMS reimbursement pathways, and FDA and EU regulatory requirements can uniquely steer Series A and B ready companies to a successful outcome. Furthermore, our team's strong relationships with leading physician, surgeon, healthcare executives and global thought leaders can create new avenues for profitability. We are also well connected with the senior management of many of the largest healthcare companies as well as private and institutional investors.

Our founders are also financial technology entrepreneurs and operational managers some of whom have a twenty year track record of creating and contributing to financial technology firms whose exits and recapitalizations have totaled over \$1.9 Billion. By assisting founders in the financial technology sector, including in emerging technologies such as AI, Machine Learning, blockchain and rapid computation, to navigate regulatory processes in areas where innovation has outpaced clear regulation is another key to success.

Our knowledge, experience, and networks are anticipated to provide us with key advantages: early looks at promising companies, acceleration of regulatory pathways, and participation in syndications with leading venture investors.

Private Investments

Less than 20%
**of Large US Businesses
are Publicly Traded³**

26% Annualized Growth in
**Managed Private Capital
over the Past Decade⁴**

\$7.3 Trillion
Private Capital Market⁴

\$500 Billion in
U.S. Venture Capital⁴

When You're Ready to Invest Beyond the Ordinary™

Contact us to set up a call.

Email: hello@mammothresearch.com
Phone: **(800) 618-2299**

1 - Source: Deloitte's 2020 Global Blockchain Survey; https://www2.deloitte.com/us/en/insights/topics/understanding-blockchain-potential/global-blockchain-survey.html?id=us:2ps:3gl:confidence:eng:cons:32019:nonem:na:IK3QtAAO:1141606376:346859115084:b:Blockchain:Blockchain_Survey_BMM:nb

2 - Source: CNBC; <https://www.cnbc.com/2019/10/21/what-the-68-trillion-great-wealth-transfer-means-for-advisors.html>

3 - Source: US Bureau of Labor Statistics, World Federation of Exchanges, Altegris. Percentage of total number of US private sector firms with 500+ employees versus listed domestic companies on US Exchanges as of March 2015

4 - Source: Wharton Venture Capital executive course, September, 2020.

Important Legal Disclosure

This document is provided to potential investors to assist in evaluating participation in the opportunity described in it. This is not an offering document. Any offer of securities in a Mammoth Fund may only be made by delivery by Mammoth Scientific, LLC to the potential investor of definitive offering and legal documents. Mammoth Scientific, LLC is an investment adviser to venture capital funds that files as an exempt reporting adviser. Status as an exempt reporting adviser does not imply a certain level of skill or training. The securities offered by Mammoth Scientific, LLC have not been registered under the Securities Act of 1933, as amended, or the securities laws of any state, or jurisdiction, in reliance upon the exemptions from registration provided by the Securities Act and Regulation D Rule 506 (c) and comparable exemptions from registration provided by other applicable securities laws.

This document contains forward-looking statements or projections. These forward-looking statements can be identified by use of forward-looking terminology such as “may”, “will”, “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” or “believe,” or the negatives thereof or comparable terminology. Due to various risks and uncertainties, actual events, results or the actual performance of the Mammoth Fund’s portfolio companies may differ materially from those reflected or contemplated in such forward-looking statements. Nothing contained in this document may be relied upon as a guarantee, promise, assurance or a representation as to the projected results, future events or performance. Mammoth Scientific, LLC disclaims any obligation to update these forward-looking statements or projections or this document in general.

Investments in the Mammoth Funds will be suitable only for certain financially sophisticated investors who meet certain eligibility requirements, have no need for immediate liquidity in their investment, and can bear the risk of an investment in the Mammoth Funds for an extended period.

There is no guarantee that the investment objectives will be achieved. Moreover, the past performance of the investment team should not be construed as an indicator of future success. All prospective investors are encouraged to consult with their own legal, tax, financial and investment advisors. All investors should make their own determination of whether to make an investment based on their own independent evaluation. Additionally, this document does not include all material terms of the offering. This document is qualified entirely by the Fund’s Operating Agreement, offering documents and other legal and governance documents.

7.21.2021

PRIVATE COMPANIES AND PRIVATE INVESTMENTS INVOLVE UNIQUE RISKS. YOU SHOULD BE AWARE THAT YOU COULD LOSE YOUR ENTIRE INVESTMENT.